Physician profile
Charles E Addington
NPI 1508837790
$5,886.29
in general payments reported to CMS, 2019-2025
41 companies · $807 in 2025
The $807 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $592 · 2021: $1,219 · 2022: $1,055 · 2023: $993 · 2024: $623 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $805.30 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $637.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $597.10 | 2019-2025 | Vraylar |
| Lilly USA, LLC | $572.39 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Mylan Specialty L.P. | $481.20 | 2019-2024 | Yupelri |
| Amgen INC. | $389.75 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $262.96 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.85 | 2020-2022 | |
| Horizon Therapeutics Plc | $229.44 | 2019-2023 | Krystexxa |
| Novo Nordisk INC | $177.82 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Penumbra, INC. | $139.52 | 2023 | Indigo System |
| Shire North American Group INC | $136.76 | 2019 | |
| Supernus Pharmaceuticals, INC. | $114.52 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $99.74 | 2019-2025 | Nuedexta, Rexulti |
| Amarin Pharma, INC. | $88.03 | 2020-2022 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Addington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.